Biogen (BIIB) PT Raised to $369 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Biogen (BIIB) PT Lowered to $272 at Cantor Fitzgerald
April 26, 2018 1:49 AM EDTCantor Fitzgerald lowered its price target on Biogen (NASDAQ: BIIB) to $272.00 (from $289.00) while maintaining a Neutral rating.
... MoreBiogen (BIIB) PT Lowered to $311 at RBC Capital
April 25, 2018 7:43 AM EDTRBC Capital lowered its price target on Biogen (NASDAQ: BIIB) to $311.00 (from $316.00) while maintaining a Sector Perform rating.
Analyst Brian Abrahams said Q1 softness stems from Spinraza and seasonality.
... MoreBiogen (BIIB) PT Lowered to $375 at Oppenheimer
April 25, 2018 7:15 AM EDTOppenheimer lowered its price target on Biogen (NASDAQ: BIIB) to $375.00 (from $400.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "A solid 1Q update addressed investor concerns on multiple fronts with decent financial results featuring an EPS beat of $6.05 vs $5.93E consensus and... More
Biogen (BIIB) PT Lowered to $325 at Leerink Partners
April 25, 2018 6:37 AM EDTLeerink Partners lowered its price target on Biogen (NASDAQ: BIIB) to $325.00 (from $365.00) while maintaining a Market Perform rating.
... MoreBiogen (BIIB) PT Lowered to $385 at Guggenheim
April 25, 2018 2:03 AM EDTGuggenheim lowered its price target on Biogen (NASDAQ: BIIB) to $385.00 (from $400.00) while maintaining a Buy rating.
... MoreUPDATE: Baird Upgrades Biogen (BIIB) to Outperform
April 25, 2018 1:08 AM EDT(Updated - April 25, 2018 4:37 AM EDT)
(updated to add analyst comment)
Baird upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform with a price target of $323.00.
Analyst Brian Skorney comments "While we have all the enthusiasm that goes with... More
UPDATE: Goldman Sachs Downgrades Biogen (BIIB) to Buy
April 25, 2018 12:56 AM EDT(Updated - April 25, 2018 4:39 AM EDT)
(updated to add analyst comment)
Goldman Sachs downgraded Biogen (NASDAQ: BIIB) from Conviction Buy to Buy with a price target of $388.00 (from $396.00).
Analyst Terrance Flynn remains Buy-rated after removing the name from the Conviction Buy... More
Biogen (BIIB) PT Lowered to $353 at Piper Jaffray
April 24, 2018 1:30 PM EDTPiper Jaffray lowered its price target on Biogen (NASDAQ: BIIB) to $353.00 (from $407.00) while maintaining a Overweight rating.
Analyst Chris Raymond comments "Remain Overweight rated on BIIB shares but also lowering estimates, price target after a Q118 top-line miss. Spinraza trends have... More
